Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06570447 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of May 15, 2025 to Feb 27, 2025v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 15, 2024 to May 15, 2025
    • Study site revised
    v3
  3. Start date: Aug 15, 2024 to Sep 15, 2024v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An open-label, single-arm, single-center, phase II clinical trial to evaluate the feasibility, efficacy and safety of Glofitamab Combination with chidamide in patients with recurrent/refractory diffuse large B-cell lymphoma.
Trial Details
NCT Number NCT06570447
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions
(from sponsor)		 Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Refractory
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov